Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

Table S7. Balance in baseline covariates of tofacitinib-treated and tocilizumab-treated RA patients, grouped by the status of previous bDMARD use, after IPTW adjustment

	bDMARD-naïve patients (n = 215)		Previous bDMARD-failure patients (n = 249)	
	Tofacitinib versus tocilizumab		Tofacitinib versus tocilizumab	
	ASD*		ASD*	
	Before IPTW	After IPTW	Before IPTW	After IPTW
Age	0.088	0.030	0.43	0.035
Male sex	0.20	0.038	0.051	0.006
RA duration	0.10	0.010	0.29	0.069
Advanced stages	0.11	0.009	0.17	0.016
Anti-CCP-positive	0.095	0.031	0.007	0.005
RF-positive	0.15	0.024	0.049	0.018
CDAI	0.030	0.024	0.050	0.055
Concurrent MTX use	0.11	0.040	0.25	0.016
Concurrent PSL use	0.41	0.026	0.33	0.007

*Balance in each of the baseline covariates was checked between the tofacitinib and tocilizumab groups before and after IPTW adjustment, separately in bDMARD-naïve patients and bDMARD-failure patients. ASD of <0.10 indicates that the baseline covariates were well balanced between the two treatment groups.

RA, rheumatoid arthritis; bDMARD, biological disease-modifying antirheumatic drug; anti-CCP, anti-cyclic citrullinated peptide antibodies; RF, rheumatoid factor; MTX, methotrexate; PSL, prednisolone; CDAI, clinical disease activity index; IPTW, inverse probability of treatment weighting; ASD, absolute standardized difference